Piramal Pharma will be increasing its stake in contract development and manufacturing organisation Yapan Bio from 74% to 100%.
Discussions with the shareholders of Yapan in this regard are under way. The final terms, including acquisition cost and the effective date, are yet to be finalised, Piramal Pharma said, announcing that the Administrative Committee of its Board has approved the exercise of the company’s call option to acquire the balance 26% equity stake. Upon completion of the transaction, Yapan will become a wholly owned subsidiary.
A CDMO based in Hyderabad’s Genome Valley, Yapan specialises in process development, characterisation and Phase I/II GMP manufacturing services for vaccines and biologics. Piramal Pharma initially in December 2021 acquired a 27.78% stake in Yapan Bio for more than ₹101 crore.
In August this year, Piramal said it has completed the acquisition of 1,46,400 equity shares from existing shareholders of Yapan for around ₹76 crore taking its shareholding, in the CDMO, from 33.33% to 74%.
With the acquisition, it will fully embed Yapan’s advanced large molecule capabilities into its integrated service offering, enabling the company to develop and scale complex biologic therapies with greater efficiency, Piramal had then said in a filing.
Published – November 19, 2026 08:45 am IST
Leave a Reply